Human papillomavirus vaccination in low-and middle-income countries: progression, barriers, and future prospective
N Ebrahimi, Z Yousefi, G Khosravi, FE Malayeri… - Frontiers in …, 2023 - frontiersin.org
Human papillomavirus (HPV) is a viral infection that, if does not go away, can cause health
problems like genital warts and cancer. The national immunization schedules for individuals …
problems like genital warts and cancer. The national immunization schedules for individuals …
[HTML][HTML] DNA methylation as a triage tool for cervical cancer screening–A meeting report
FR Burdier, B Nedjai, RDM Steenbergen… - Preventive medicine …, 2024 - Elsevier
Introduction DNA methylation is proposed as a novel biomarker able to monitor molecular
events in human papillomavirus (HPV) infection pathophysiology, enabling the distinction …
events in human papillomavirus (HPV) infection pathophysiology, enabling the distinction …
[HTML][HTML] An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses–A meeting report
FR Burdier, C Eklund, I Baussano, FC Mariz… - Preventive Medicine …, 2023 - Elsevier
The 12th HPV Prevention and Control meeting was held on June 2–3, 2022, in Antwerp,
Belgium. This technical meeting focused on several topics. This report summarises the …
Belgium. This technical meeting focused on several topics. This report summarises the …
Modeling the transmission dynamics and vaccination strategies for human papillomavirus infection: An optimal control approach
F Saldaña, JA Camacho-Gutiérrez… - Applied Mathematical …, 2022 - Elsevier
Human papillomavirus (HPV) vaccines have been introduced in several countries and have
shown positive results in reducing HPV infection and related diseases. Nevertheless …
shown positive results in reducing HPV infection and related diseases. Nevertheless …
Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic
A Schuman, KS Anderson, AT Day… - Expert review of …, 2022 - Taylor & Francis
Introduction Oropharyngeal cancer (OPC) will be among the most common cancers in men
by 2045 due to a rapid rise in human papillomavirus (HPV)–related OPC. Those who survive …
by 2045 due to a rapid rise in human papillomavirus (HPV)–related OPC. Those who survive …
Prevention and control of HPV and HPV-related cancers in France: the evolving landscape and the way forward–a meeting report
DN Waheed, CW Olivier, D Riethmuller, EL Franco… - BMC proceedings, 2023 - Springer
Misinformation regarding HPV vaccine safety and benefits has resulted in low coverage
within the eligible French population. HPV vaccination is safe and efficacious in preventing …
within the eligible French population. HPV vaccination is safe and efficacious in preventing …
Assessment of acceptability and determinants of uptake and schedule completion of human papillomavirus (HPV) vaccine by 25 to 45 years old women in Slovenia
J Mlakar, A Oštrbenk Valenčak, J Kežar… - Vaccines, 2023 - mdpi.com
HPV immunization programs are mainly focused on girls and boys, but adult women and
men could also benefit from vaccination. A multinational CoheaHr-WP4 study investigated …
men could also benefit from vaccination. A multinational CoheaHr-WP4 study investigated …
[HTML][HTML] Human Papillomavirus Prevention by Vaccination: A Review Article
SH Charde, RA Warbhe - Cureus, 2022 - ncbi.nlm.nih.gov
Cervical cancer is the most common cancer among women worldwide. It is caused by
infection due to human papillomavirus. There are some screening tests available for its …
infection due to human papillomavirus. There are some screening tests available for its …
[PDF][PDF] Vaccines against emerging sexually transmitted infections: current preventive tools and future perspectives
AR Raccagni, F Alberton, A Castagna… - New …, 2022 - newmicrobiologica.org
Angelo Roberto Raccagni E-mail: raccagni. angelo@ hsr. it; Francesca Alberton E-mail:
alberton. francesca@ hsr. it© 2022 by EDIMES-Edizioni Internazionali Srl. All rights reserved …
alberton. francesca@ hsr. it© 2022 by EDIMES-Edizioni Internazionali Srl. All rights reserved …
CIGB-300 peptide targets the CK2 phospho-acceptor domain on Human Papillomavirus E7 and disrupts the Retinoblastoma (RB) complex in cervical cancer cells
AC Ramón, O Basukala, P Massimi, M Thomas… - Viruses, 2022 - mdpi.com
CIGB-300 is a clinical-grade anti-Protein Kinase CK2 peptide, binding both its substrate's
phospho-acceptor site and the CK2α catalytic subunit. The cyclic p15 inhibitory domain of …
phospho-acceptor site and the CK2α catalytic subunit. The cyclic p15 inhibitory domain of …